Grant RDF
pages:- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- more...
- A Phase 3, Randomized, Dbl-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Gs-1101 (Cal-101).....
- A PHASE 3, RANDOMIZED, DOUBLE-BLIND STUDY OF TIVANTINIB (ARQ 197) IN SUBJECTS WITH MET DIAGNOSTIC-HIGH INOPERABLE HEPATOCELLULAR CARCINOMA (HCC) TREATED WITH ONE PRIOR SYSTEMIC THERAPY
- A Phase 3, Randomized, Double-blind, Controlled Study of Cabozantinib (XL184) vs Placebo in Subjects with Hepatocellular Carcinoma Who Have Received Prior Sorafenib
- A Phase 3, Randomized, Double-Blind, Cross-Over, Active- Controlled Study of the Efficacy and Safety of Hpn-100-006
- A Phase 3, Randomized, Double-Blind, Multi-Center Study to Compare the Efficacy and Safety of Micafungin Versus
- A Phase 3, Randomized, Double-Blind, Placebo-Controlled Evaluating the Efficacy and Safety of Gs-1101 (Cal-101)...
- A Phase 3, Randomized, Double-Blind, Placebo-Controlled Safeand Efficacy Study of Dimebon in Patients With Mild-to-Moder
- A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Abiraterone Acetate (Cb7630) Plus Prednisone......
- A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Effects of Ranolazine on Major Adverse . . .
- A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of the Safety and Efficacy of Orbec.....
- A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Trial to Evaluate Safety & Efficacy of Tx-004..
- A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Aztreonam for Inhalation Solution.....
- A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Safety
- A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Safety...
- A Phase 3, Randomized, Double-blind, Placebo-controlled-group, Multicenter Protocol to Evaluate the Safety and Efficacy of Ustekinumab(CNTO1275)
- A Phase 3, Randomized, Double-Blind, Placobo-Controlled, Multi-Center Trial to Evaluate the Safety and Efficacy...
- A Phase 3, Randomized, Multi-Center Open Label Study to Evaluate the Efficacy Safety and Tolerability of Albumin........
- A Phase 3, Randomized, Multi-Center Open Label Study to Evaluate the Efficacy Safety and Tolerability of Albumin........
- A Phase 3, Randomized, Multi-Center Study to Evaluate the Efficacy and Safety of Albumin Interferon Alfa-2b (alb-IFN) in Combination with Ribavirin Compared with Peginterferon Alfa-2a (PEGASYS or PEG-IFNa2a) in Combination with Ribavirin in Interferon Alfa Naive Subjects with Chronic Hepatitis C Genotype 1
- A Phase 3, Randomized, Multi-Center Study to Evaluate the Efficacy and Safety of Albumin Interferon Alfa-2b (alb-IFN) in Combination with Ribavirin Compared with Peginterferon Alfa-2a (PEGASYS or PEG-IFNa2a) in Combination with Ribavirin in Interferon Alfa Naive Subjects with Chronic Hepatitis C Genotype 2 or 3
- A Phase 3, Randomized, Multi-Center, Open-Label Study to Evaluate the Efficacy Safety and Tolerability of Albumin.......
- A Phase 3, Randomized, Open-Label Study of the Safety and Efficacy of Two Dose Levels of Interferon Alfacon-1 (Infergen, CIFN) plus Ribavirin Administered Daily for 48 Weeks Versus No-treatment in Hepatitis C Infected Patients Who Are Nonresponders to Previous Pegylated Interferon Alfa plus Ribavirin Therapy
- A Phase 3, Randomized, Open-Label Study of the Safety and Efficacy of Two Dose Levels of Interferon Alfacon-1 (Infergenīĸ, CIFN) plus Ribavirin Administered Daily for 48 Weeks Versus No-treatment in Hepatitis C Infected Patients Who Are Nonresponders to Previous Pegylated Interferon Alfa plus Ribavirin Therapy
- A Phase 3, Randomized, Opn-Lbl Study of the Safety and Efficacy of Two Dose Levels of Daily Interferon Alfacon-1...........
- A Phase 3, Randomized, Placebo Controlled, Blinded, Multicenter Stuyd of the Induction of Clinical Response.....
- A Phase 3, Rd/Bd Multicenter, Placebo-Controlled, Parallel- Group Study to Evaluate the Efficacy & Safety of Lumacaftor
- A Phase 3, Safety & Efficacy Study of Boceprevir in Previousuntreated Subjects With Chronic Hepatitis C Genotype 1
- A Phase 3, Twelve Week, Multicenter, Double-Blind, Random...Efficacy and Safety Study of Mesafem Capsules in Treatment..
- A Phase 3,Randomized, Double-Blind, Placebo-Controlled Studye Effects of Ranolazine on Major Adverse Cardiovascular....
- A Phase 3...Parallel Group Trial of the Effects of Titrated Oral Samsca (Tolvaptan) 15, 30, or 60 Mg Qd Compared To....